Oppenheimer upgraded shares of Crispr Therapeutics (NASDAQ:CRSP) from a market perform rating to an outperform rating in a research report sent to investors on Tuesday, Briefing.com Automated Import reports. The brokerage currently has $65.00 price target on the stock. Oppenheimer also issued estimates for Crispr Therapeutics’ Q1 2020 earnings at ($0.87) EPS, Q2 2020 earnings at ($0.95) EPS, Q3 2020 earnings at ($1.29) EPS, Q4 2020 earnings at ($1.38) EPS, FY2021 earnings at ($4.29) EPS, FY2022 earnings at ($4.70) EPS and FY2023 earnings at ($1.07) EPS.
A number of other research analysts have also recently commented on CRSP. Zacks Investment Research cut Crispr Therapeutics from a hold rating to a sell rating in a research note on Monday, September 30th. TheStreet upgraded Crispr Therapeutics from a d rating to a c rating in a report on Monday, October 28th. BTIG Research increased their price objective on Crispr Therapeutics from $51.00 to $59.00 and gave the company a positive rating in a report on Tuesday, July 30th. BidaskClub upgraded Crispr Therapeutics from a sell rating to a hold rating in a report on Thursday, October 31st. Finally, Needham & Company LLC restated a buy rating and issued a $62.00 price objective on shares of Crispr Therapeutics in a report on Wednesday, July 31st. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and twelve have given a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $57.95.
Shares of Crispr Therapeutics stock traded up $1.81 on Tuesday, hitting $56.87. The stock had a trading volume of 763,200 shares, compared to its average volume of 749,333. Crispr Therapeutics has a twelve month low of $22.22 and a twelve month high of $57.40. The stock has a market cap of $3.04 billion, a price-to-earnings ratio of -16.53 and a beta of 3.15. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The business’s 50 day moving average is $43.31 and its two-hundred day moving average is $44.57.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the completion of the sale, the director now directly owns 7,500 shares in the company, valued at $412,500. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 21.40% of the company’s stock.
Institutional investors have recently modified their holdings of the business. Benjamin Edwards Inc. grew its holdings in Crispr Therapeutics by 96.4% during the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock worth $26,000 after acquiring an additional 268 shares during the period. NEXT Financial Group Inc grew its holdings in Crispr Therapeutics by 915.0% during the 3rd quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after acquiring an additional 549 shares during the period. US Bancorp DE grew its holdings in Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after acquiring an additional 526 shares during the period. Coastal Investment Advisors Inc. acquired a new stake in Crispr Therapeutics during the 3rd quarter worth about $26,000. Finally, BSW Wealth Partners acquired a new stake in Crispr Therapeutics during the 2nd quarter worth about $39,000. Hedge funds and other institutional investors own 51.09% of the company’s stock.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: If I purchase shares through a brokerage account, am I the holder of record?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.